Erste Asset Management GmbH Purchases Shares of 636,065 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Erste Asset Management GmbH purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 636,065 shares of the biotechnology company's stock, valued at approximately $79,425,000. Sarepta Therapeutics comprises approximately 1.0% of Erste Asset Management GmbH's portfolio, making the stock its 20th largest position. Erste Asset Management GmbH owned about 0.67% of Sarepta Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Innealta Capital LLC bought a new stake in Sarepta Therapeutics during the 2nd quarter worth about $31,000. Nkcfo LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $43,000. Huntington National Bank increased its holdings in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Riggs Asset Managment Co. Inc. raised its position in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 75 shares during the last quarter. Finally, UMB Bank n.a. raised its position in Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 197 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

SRPT stock traded down $4.60 during trading hours on Friday, reaching $133.34. The stock had a trading volume of 777,554 shares, compared to its average volume of 1,375,611. The stock has a market capitalization of $12.74 billion, a PE ratio of 106.67 and a beta of 0.81. The stock has a 50-day simple moving average of $122.50 and a 200 day simple moving average of $131.48. Sarepta Therapeutics, Inc. has a fifty-two week low of $78.67 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on SRPT shares. Citigroup dropped their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. Guggenheim boosted their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. UBS Group increased their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research note on Tuesday, September 17th. Piper Sandler decreased their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday. Finally, Evercore ISI dropped their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $175.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.